2015 American Transplant Congress
Antibodies Directed Against HLA-DQ Are Significantly Associated to Complement Activation In Vitro
Background: C1q-binding HLA antibodies (HLAabs) have been related to acute rejection and long-term graft loss. The characteristics of these antibodies and factors associated to complement…2015 American Transplant Congress
Prediction of Acute Antibody Mediated Rejection in Antibody Incompatible Renal Transplantation Using Machine Learning for Wide Data
The dynamic field of renal transplantation is characterised by limited access to data, the high cost of equipment and underlying complexity of immunological responses to…2015 American Transplant Congress
Bortezomib Treatment in Antibody Mediated Rejection After Kidney Transplantation
BackgroundSeveral studies demonstrated bortezomib therapy for antibody-mediated rejection (AMR) in renal transplants. However, the treatment efficacy according to target antigen or occurrence time of AMR…2015 American Transplant Congress
Desensitization Protocol Including Concomitant Bortezomib and Rituximab Did Not Reduce Calculated PRA Nor Mean MFI Values Among Waitlisted Patients for Deceased Donor Kidney Transplantation
Highly sensitized (HS) patients (pts) seldom have chance to receive deceased donor kidney transplant (DDKT). A desensitization (DES) program including bortezomib was employed to facilitate…2015 American Transplant Congress
Intermittent High Dose Intravenous Immunoglobulin as Treatment for Donor Specific Antibodies in Renal Transplant Recipients
Background: Donor-specific HLA antibody (DSA) formation in post-renal transplant patients is associated with chronic rejection and graft failure. Previous studies in our population have indicated…2015 American Transplant Congress
Immunoglobulin G Donor-Specific Anti-HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury
Experimental and clinical data suggest that antibodies have different pathogenicities according to their IgG subclasses. We investigated the association between IgG subclasses of circulating anti-HLA…2015 American Transplant Congress
Incidence of De Novo Donor Specific Antibodies in Kidney Transplant Recipients
The reported incidence and risk factors for the development of de novo donor specific antibodies (dnDSA) are variable. Although dnDSA is a negative predictor of…2015 American Transplant Congress
Interference of Therapeutic Antibodies Used in Desensitization Protocols On Lymphocytotoxicity Crossmatch Results
Background: Therapeutic antibodies used to desensitize patients awaiting a human leukocyte antigen (HLA) or ABO-mismatched graft are suspected to interfere with the lymphocytotoxicity crossmatch (LCT-XM)…2015 American Transplant Congress
CPRA Values Are Substantially Increased for Some Candidates Subsequent to Inclusion of Unacceptable C-locus (UA-C) Antigens While Listing Practices Remain Unchanged
1UNOS, Richmond; 2Emory University Hospital, Atlanta; 3Stanford University, Palo Alto.
Background: CPRA is the % of deceased donors expected to have one or more UAs with a given candidate. Prior to 12/5/13, candidates with UA-C…2015 American Transplant Congress
Assessment of Circulating HLA-Specific Alloreactive Memory B Cells Reveals Surreptitious Immunized Kidney Transplant Recipients at High Risk of Antibody-Mediated Rejection
Even though current bead-based multiplex techniques enable an accurate assessment of circulating HLA-specific antibodies, a more comprehensive study of the humoral alloimmune response through the…